logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    
Gilead Sciences Inc.

Gilead Sciences Inc. (GILD)

Follow

Details

Wall

Profile


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Issuer Information

Exchange: NASDAQ
Market Cap: 85694490248
CEO: John C. Martin
Employees: 5000
Issuer Type: CS
Auditor: Ernst & Young LLP
Last Audit: UQ
CIK: 882095
Sector: Healthcare
Industry: Biotechnology
Sub-Industry: Biotechnology
NAICS: Biological Product (except Diagnostic) Manufacturin (325414)
SIC: 2836
Last earning call url:
Slideshare slide url:

Contact Information

Main phone: +1 650 574-3000
Address: 333 Lakeside Drive
Address 2:
State: CA
City / Town: Foster City
Country: USA
Postal Code: 94404
Fax:

Videos

No public videos available.

Blog

No Result Found.

News

Stock in health insurers is broadly down on Thursday morning. Every major health insurer saw shares down in early trading, with a disappointing earnings report from industry-leader UnitedHealth Group Inc.…
Just two days after the S&P 500 hit an all-time high, big sell-offs in biotech and tech took the market to its news, with the Nasdaq recording its worst day…
The race to produce the first effective Hepatitis C drug, and capture the massive profits that come with it, appears to have been won by Gilead Sciences (GILD) . At…
After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim…
In another rough day of trading for American stocks, all three major indices lost more than a percentage point, with the Nasdaq leading the way with losses that briefly exceeded…
In early March, shares of Gilead ($GILD) notched a five-year-high of $84.88 per share thanks to the company’s Hepatitis C super drug Sovaldi. Costing $1,000 for a single tablet, Sovaldi…
While it’s still too early to tell, investors appear to be bailing on biotech stocks. Or, at least, they appear to be trying to make up their minds about it.…
Wall Street rallied early in Monday’s session, and maintained gains consistently throughout trading, with all indices once again approaching intraday highs to end the first quarter of 2014. Investors looking…
Henry Waxman (D-CA) has long been one of the more influential members of the House of Representatives, and he's also long been a thorn in the side to many on…
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He understands the sector, the entrepreneurs…

Trending

Social Mentions about your company in the last seven days
Tom Silver
18 Apr 14 23:13:46
$GILD RBC:Sovaldi weekly TRx tracked +156% higher than what Incivek did during its first full quarter of launch,=$1.5B+ in Q1:14 sales estim
Eric M. Vihlen
18 Apr 14 23:07:53
@jimcramer's Four Horsemen of #Biotech $CELG, $GILD, $BIIB, and $REGN and their pipeline of important drugs. p.155 #GettingRichCarefully
Eternity101
18 Apr 14 22:42:18
RT @TomSilver39: $BIIB $PFE $GILD Exclusive: Biogen prices hemophilia drug on par with older therapies http://t.co/zT5eWnxQ17 via @reuters
Dr. Paul DeSantis
18 Apr 14 22:08:02
@MarkSchoenebaum @BioTrader12 @Asthika it happens to everyone buddy, hope $GILD isnt mine ;)
Allen
18 Apr 14 21:54:51
RT @ScripDonnaDC: BMS seeks FDA OK for atazanavir/cobicistat FDC in HIV http://t.co/XvsjOUX5PN $BMY #FDA #HIV #pharma #atazanavir #cobicist…
Allen
18 Apr 14 21:54:21
RT @zakariaalcs: Day 1: Sofosbuvir (Sovaldi) plus Daclatasvir - Hepatitis C - MedHelp http://t.co/o3eJb6gxgL $GILD #HepC (must keep our e…
Tom Silver
18 Apr 14 21:13:01
$BIIB $PFE $GILD Exclusive: Biogen prices hemophilia drug on par with older therapies http://t.co/zT5eWnxQ17 via @reuters
Mariano Pazzaglia
18 Apr 14 19:26:05
@rushtonjdr @BikeRieder @Ethane28 @rajramaswamy @psuvafan007 And $GILD will be sniffing around for the next Pharmasett to buyout $ARWR.
Sri Raman
18 Apr 14 19:04:23
Earnings Surprise Forecast Picks: Alpha Here and Now | Alpha Now | Thomson Reuters: http://t.co/TKpNYomLsH $UAL $GILD
Ronald J. Perez, PhD
18 Apr 14 18:54:37
RT @ianestepan: Sovaldi total scripts of 7,870, down 2% from last week. New Rx were 3,645, down 6% w/w $GILD
Jamie Rushton
18 Apr 14 18:52:53
@BikeRieder @Ethane28 @rajramaswamy @MPazaglia @psuvafan007 let's hope. But $GILD will generate it's mkt cap in cash over the next 7yrs.
Jaydan Gelson
18 Apr 14 18:35:30
Free research on $KLAC $GILD $HCC $PCLN Check out http://t.co/n98hTVn0jN
Freshy Go Variety
18 Apr 14 17:44:55
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
Stockaholics
18 Apr 14 17:43:58
Our Penny Stock Picks gained 5,000% in 4 months! Get the next Pick Early: http://t.co/5B5saivZk0 $GILD $NWSA $EBAY
Scott Forman
18 Apr 14 17:36:35
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
Heidi Wagler
18 Apr 14 17:15:30
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
☞ ✤ Ivana Glogovac ✪
18 Apr 14 17:08:43
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
Naha Gupta
18 Apr 14 16:43:34
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
Christopher Sandys
18 Apr 14 16:41:18
RT @davidnelsoncfa: $GILD ’s $1000 Pill - Is it worth It? Why I’m back in. http://t.co/Qzd1AsxH2L http://t.co/Zb5suOJ3f8
Donte Aldaine
18 Apr 14 16:37:59
$GILD Todays movers to research $YUM $ONNN $FB #equity http://t.co/ohDL3dwAiE
BATTLE THE BTK
18 Apr 14 16:20:02
@ColfaxCapital @MarkSchoenebaum 50k eastern european and indian cpu sci majors have a strange inkling to buy $gild and they dont know why.
Sujatha Ramanathan
18 Apr 14 15:55:47
RT @ianestepan: Sovaldi total scripts of 7,870, down 2% from last week. New Rx were 3,645, down 6% w/w $GILD
12Stocks.com
18 Apr 14 15:26:54
Weekly Nasdaq100 #Stocks Trend $MU $VIP $SNDK $QCOM $FISV $CSCO $COST $CHRW $YHOO $GILD $BIDU $LINTA $WDC $PCLN @ http://t.co/wz4pxpINCJ
12Stocks.com
18 Apr 14 15:26:54
Weekly Nasdaq100 #Stocks Performance $MU $VIP $SNDK $YHOO $GILD $MNST $CHRW $ADSK $EXPE $TRIP $QCOM $BIDU more@ http://t.co/wz4pxpINCJ
12Stocks.com
18 Apr 14 15:26:53
Weekly S&P100 #Stocks Performance $COP $GILD $CVX $NOV $MS $WAG $HAL $KO $ABT $C $QCOM $MA $XOM $GE $DVN more@ http://t.co/cKkr8ctphu
Mo
18 Apr 14 15:04:46
@MarkSchoenebaum mark I feel like your name has been pasted to almost 70% of past 8 wks of $gild and other bio articles. Plus tweet images
Calloway Domville
18 Apr 14 14:02:58
Seeking the next stock like $ENDP $GILD $MAT $CLF Try this http://t.co/kpQOkSVWBr
Abccookies
18 Apr 14 13:48:17
RT @Barack01: $GILD GS Analyst thinks $1 to $1.5 billion sales for Sovald in first qtr...wow. GILD should crush earnings.
LHommeAncien
18 Apr 14 13:47:57
@ianestepan $gild finally if Sovaldi px cut 25%, new pAtient run rate in $B not under 6B since 2/14w
LHommeAncien
18 Apr 14 13:42:56
@ianestepan $gild new patient annul run rate$BSovaldi since 2/21wk was 8.4,10.2,9.2,11.0,9.2,8.1,10.7,8.8 Est >36k patient ytd est 130k/'14
LHommeAncien
18 Apr 14 13:36:39
@ianestepan $gild new patients put on Sovaldi were 2512 which compares w/prior 7wks @ 2423(wk2/11),2924,2648,3170,2633,2330,3071.2512/w~9By
Informer
18 Apr 14 13:30:05
$GILD: Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings http://t.co/Nn1JhG06Nu
LHommeAncien
18 Apr 14 13:21:56
@ianestepan $gild
Barack01
18 Apr 14 13:13:52
$GILD GS Analyst thinks $1 to $1.5 billion sales for Sovald in first qtr...wow. GILD should crush earnings.
Stockaholics
18 Apr 14 13:06:58
Members saw 5,000% gains on Penny Stock Alert's in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $GILD $NWSA $EBAY
Orson Gunnero
18 Apr 14 13:04:39
$GILD #Pennystock Research on $PHM $CB $HIT #NSE http://t.co/tdbtg0ybAo
GavinGreenberg
18 Apr 14 12:26:36
$GILD: Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings http://t.co/yspiB2oJAy
Daniel A. Valle
18 Apr 14 12:08:32
RT @IBDinvestors: Biohazard? #Gilead Leads 5 Big-Cap Biotech Earnings After Stocks Tumble http://t.co/XgFaVyT88W $CELG $BIIB $GILD http://t…
Ryan York
18 Apr 14 11:54:13
RT @IBDinvestors: Biohazard? #Gilead Leads 5 Big-Cap Biotech Earnings After Stocks Tumble http://t.co/XgFaVyT88W $CELG $BIIB $GILD http://t…
Roy Friedman
18 Apr 14 11:54:10
.@biosimilarz @ianestepan Regardless,we're in prelimnry commercial phase until all-oral GT1 regimens from $GILD & $ABBV/ $ENTA are approved.
PharmafocusEditor
18 Apr 14 11:42:25
RT @FiercePharma: Gilead's #Sovaldi, GSK's #Anoro stand out in 2014's blockbuster crop, report says http://t.co/DP3HaRhJON $GSK $GILD #phar…
Cortellis
18 Apr 14 11:41:06
RT @FiercePharma: Gilead's #Sovaldi, GSK's #Anoro stand out in 2014's blockbuster crop, report says http://t.co/DP3HaRhJON $GSK $GILD #phar…
Stock Herald
18 Apr 14 11:29:37
$GILD: Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings http://t.co/PvBxls62CU
Beverley Marinoh
18 Apr 14 11:25:11
$TRIP It could be breaktout time on $KLAC $GILD $RT #investing http://t.co/Utnvzje88a
Legend Boulstridge
18 Apr 14 11:07:53
Get the latest on $KLAC $GILD $ABBV $SLV #NASDAQ http://t.co/9K54wDniGl
Insider Trade Alerts
18 Apr 14 11:06:23
$APC Buying or selling? $RRC $GILD $SSO #economy http://t.co/ILCSzqEHWM
Dmitri Magnuson
18 Apr 14 11:04:54
Best research on #stocks such s $AMZN $GILD $ABBV $LIVE #equity http://t.co/EPHhjEvbp2
Matt
18 Apr 14 10:40:21
RT @IBDinvestors: Biohazard? #Gilead Leads 5 Big-Cap Biotech Earnings After Stocks Tumble http://t.co/XgFaVyT88W $CELG $BIIB $GILD http://t…

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.